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Accelerating timelines to deliver stable cell lines with high productivity is challenging, especially for biologics 
portfolios which include complex recombinant vaccine constructs.  The VRC’s current integrated approach to 
shorten CHO cell line development timeline utilizes host cells pre-adapted to production medium, optimization of 
the expression vectors, improved pre and post-transfection methodology, automated ClonePixTM technology and 
top clone selection and ranking in micro-scale ambr bioreactor technology.  This platform was developed with 
monoclonal antibodies as model proteins.  While this integrated platform enabled generation of high yielding 
clones expressing monoclonal antibodies, it was initially much less successful with a difficult to express 
recombinant stabilized trimeric RSV F protein.  Initial stable CHO cell lines produced the RSV F protein at very 
low levels that were not suitable for GMP manufacturing and the protein did not have quality attributes similar to 
the initial transient expression-based research protein.  The RSV F trimer requires enzymatic cleavage of the 
protein for proper folding and trimer formation.  However, the need for stable co-expression of a furin-like 
molecule in CHO cells was initially unknown. This case study summarizes the successful development of stable 
CHO cell lines expressing the stabililzed RSV F trimer and a cell line development protocol for difficult to 
express trimeric viral glycoproteins for clinical manufacturing.  Implications for cell line development of next 








































Figure 1.  7-day CHO batch shake flask 
harvest titer using three anti-RSV monoclonal 
antibodies 
Figure 2.  14-day CHO Ambr fed-batch titer 
